Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate proceeds anticipated to fund operations into 2029 – AUSTIN, TX and DURHAM, NC, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis fact ...